PTGX Q3 2025 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+0.8% YoY

Gross Profit

$5M100.0% margin

Operating Income

-$46M-985.2% margin

Net Income

-$39M-834.9% margin

EPS (Diluted)

$-0.62

QoQ Revenue Growth

-15.0%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$702M

Total Liabilities

$56M

Stockholders' Equity

$645M

Cash & Equivalents

$114M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$5M	+0.8%
Gross Profit	$5M	$5M	+0.8%
Operating Income	-$46M	-$41M	-12.0%
Net Income	-$39M	-$33M	-18.5%